Chen Keyao, Wang Jingjing, Yang Meng, Deng Shaoqiong, Sun Li
Gynecology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China.
Biomedicines. 2025 Jan 12;13(1):168. doi: 10.3390/biomedicines13010168.
BACKGROUND/OBJECTIVES: It remains challenging to treat recurrent ovarian cancer effectively as traditional interventions like chemotherapy and surgery have limited long-term efficacy, highlighting an urgent need for innovative approaches. Immunotherapy offers potential advantages in modulating the immune response against tumor cells and has emerged as a promising strategy in ovarian cancer management. This review discusses various immunotherapy modalities, including active and passive immune strategies, for recurrent ovarian cancer.
We systematically reviewed recent immunotherapy advances for recurrent ovarian cancer, including the efficacy and mechanisms of single and dual immune checkpoint inhibitors, checkpoint inhibitor combinations with chemotherapy or radiotherapy, anti-angiogenic agents, PARP inhibitors, antibody-drug conjugates (ADC), tumor vaccines, and adoptive cell therapies (ACT). Additionally, we assessed emerging research on biomarkers predictive of immunotherapy responsiveness in ovarian cancer.
The findings indicate that immunotherapy, particularly combinations involving immune checkpoint inhibitors and other agents, demonstrates promising efficacy in recurrent ovarian cancer, with some therapies showing enhanced benefits in specific subtypes. The immune microenvironment in platinum-sensitive and -resistant cases exhibits distinct immunological profiles, influencing therapy outcomes. Several potential biomarkers have been identified, potentially aiding in patient stratification and treatment optimization.
Immunotherapy significantly advances recurrent ovarian cancer treatment, with various combinations potentially improving outcomes. Further research on predictive biomarkers and immune microenvironment characteristics is crucial for personalizing immunotherapy approaches and enhancing their efficacy in managing recurrent ovarian cancer.
背景/目的：由于化疗和手术等传统干预措施的长期疗效有限，有效治疗复发性卵巢癌仍然具有挑战性，这凸显了对创新方法的迫切需求。免疫疗法在调节针对肿瘤细胞的免疫反应方面具有潜在优势，并已成为卵巢癌治疗中一种有前景的策略。本综述讨论了用于复发性卵巢癌的各种免疫疗法，包括主动和被动免疫策略。
我们系统回顾了复发性卵巢癌免疫疗法的最新进展，包括单药和双药免疫检查点抑制剂、免疫检查点抑制剂与化疗或放疗联合、抗血管生成药物、PARP抑制剂、抗体药物偶联物（ADC）、肿瘤疫苗和过继性细胞疗法（ACT）的疗效和机制。此外，我们评估了关于预测卵巢癌免疫疗法反应性的生物标志物的新兴研究。
研究结果表明，免疫疗法，特别是涉及免疫检查点抑制剂和其他药物的联合疗法，在复发性卵巢癌中显示出有前景的疗效，一些疗法在特定亚型中显示出更大的益处。铂敏感和耐药病例的免疫微环境表现出不同的免疫特征，影响治疗结果。已经确定了几种潜在的生物标志物，可能有助于患者分层和治疗优化。
免疫疗法显著推进了复发性卵巢癌的治疗，各种联合疗法可能改善治疗结果。进一步研究预测性生物标志物和免疫微环境特征对于个性化免疫疗法方法和提高其在复发性卵巢癌治疗中的疗效至关重要。
